Avidus Management Group Inc
Avidus Management Group Inc. develops, acquires, and operates direct sales and network marketing companies in the consumer health and wellness market in the United States. The company also offers nutraceuticals and health aids; customized nutritional, diet, and exercise plans; and various supplements comprising natural ingredients. The company's principal products include RealW8, a weight loss su… Read more
Avidus Management Group Inc (ASNHF) - Net Assets
Latest net assets as of September 2015: $-4.02 Million USD
Based on the latest financial reports, Avidus Management Group Inc (ASNHF) has net assets worth $-4.02 Million USD as of September 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($652.54K) and total liabilities ($4.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.02 Million |
| % of Total Assets | -615.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Avidus Management Group Inc - Net Assets Trend (2011–2014)
This chart illustrates how Avidus Management Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Avidus Management Group Inc (2011–2014)
The table below shows the annual net assets of Avidus Management Group Inc from 2011 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-12-31 | $-5.08 Million | -106.73% |
| 2013-12-31 | $-2.46 Million | -21.31% |
| 2012-12-31 | $-2.03 Million | -25.39% |
| 2011-12-31 | $-1.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avidus Management Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 749563800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.59 Million | % |
| Other Components | $1.22 Million | % |
| Total Equity | $-5.21 Million | 100.00% |
Avidus Management Group Inc Competitors by Market Cap
The table below lists competitors of Avidus Management Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CONFERIZE A/S DK -1
F:5IJ
|
$10.14 |
|
Vast Solutions Inc
PINK:VTON
|
$10.34 |
|
MTQCF
PINK:MTQCF
|
$10.36 |
|
Tianrong Medical Group Inc
PINK:TNMD
|
$10.36 |
|
Greene Concepts Inc
PINK:INKW
|
$10.09 |
|
TOGIW
PINK:TOGIW
|
$10.08 |
|
PreVu Inc
PINK:PRVU
|
$10.06 |
|
TERTIARY MINERALS (TMU.SG)
STU:TMU
|
$9.95 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avidus Management Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from -2,867,984 to -5,210,996, a change of -2,343,012.
- Net loss of 4,127,722 reduced equity.
- Share repurchases of 395,410 reduced equity.
- Other factors increased equity by 2,180,120.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.13 Million | -79.21% |
| Share Repurchases | $395.41K | -7.59% |
| Other Changes | $2.18 Million | +41.84% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Avidus Management Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Avidus Management Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.72%
- • Asset Turnover: 8.88x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -163.09% | 10.99x | 0.00x | $-2.85 Million |
| 2012 | 0.00% | -23.66% | 38.80x | 0.00x | $-692.09K |
| 2013 | 0.00% | -141.66% | 11.45x | 0.00x | $-2.15 Million |
| 2014 | 0.00% | -99.72% | 8.88x | 0.00x | $-3.61 Million |
Industry Comparison
This section compares Avidus Management Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avidus Management Group Inc (ASNHF) | $-4.02 Million | 0.00% | N/A | $10.12 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |